ASCO 2020: Overall survival benefit from secondary cytoreductive surgery, and results from SOLO-2 and FORWARD II for recurrent ovarian cancer

8th June 2020 (Last Updated June 8th, 2020 10:11)

ASCO 2020 Virtual Scientific Program, which took place 29 May – 2 June, reported results from clinical trials, highlighting a number of key developments in ovarian cancer treatment, which collectively show the value of innovative therapies in various patient subgroups, offering guidance to the treatment of recurrent ovarian cancer.

One of the highly anticipated presentations in ASCO 2020 was results from DESKTOP III/ENGOT-ov20 trial (abstract #6000), which demonstrated a clear survival benefit from secondary cytoreductive surgery in recurrent ovarian cancer. Read more here.